<DOC>
	<DOC>NCT01312714</DOC>
	<brief_summary>Vitamin D deficiency is highly prevalent among dialysis patients, and has been associated with cardiovascular risk factors such as increased aortic pulse wave velocity, blood pressure, inflammation, and brain natriuretic peptide. This study will evaluate the effect of 26 weeks of vitamin D3 supplementation in patients with end stage renal disease.</brief_summary>
	<brief_title>Vitamin D3 Supplementation in Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Hemodialysis or peritoneal dialysis &gt; 3 months Hypercalceamia Cancer Inability to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Peritoneal dialysis</keyword>
	<keyword>Vitamin D Deficiency</keyword>
	<keyword>blood pressure</keyword>
	<keyword>arterial stiffness</keyword>
	<keyword>Heart function</keyword>
	<keyword>Renin-angiotensin system</keyword>
	<keyword>Calcium</keyword>
	<keyword>FGF-23</keyword>
	<keyword>Brain natriuretic peptide</keyword>
</DOC>